Company profile
Sarepta Therapeutics, Inc.
NASDAQ: SRPT · Healthcare · Biotechnology
#117 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
70BFH 62DQ 79GM 65SS 86
v0.1 · 65/100 weight · provisional
↑ Piotroski F, revenue growth (YoY) · ↓ growth stability, return on equity
Methodology →Revenue TTM
$2.2B
Rev growth YoY (TTM)
-2.2%
Net income (FY)
-$713.4M
Employees
835
as of 2026-08-09
Market cap
$1.8B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.9B$1.9B2025
Net income-$713.4M-$713.4M2025
Operating income-$699.8M-$699.8M2025
Total assets$3.3B$3.3B2025
Liabilities$2.2B$2.2B2025
Equity$1.1B$1.1B2025
Revenue trend
FY2025 – FY2025 · USD
FY25
FY25
FY25
FY24
FY25
FY25
FY25
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Sarepta Therapeutics, Inc.’s revenue?
Sarepta Therapeutics, Inc. booked $1.9B in FY2025 revenue, growing 367% year over year — faster than 93% of Healthcare companies we track, at a -38.3% net margin.
Peers · Healthcare
Clover Health Investments, Corp.58CPediatrix Medical Group, Inc.76B+Evolent Health, Inc.60CInteger Holdings Corporation84B+Healthcare Services Group, Inc.87AAmerican Oncology Network, Inc.——Neighbors
Middlesex →Key facts
CEODouglas S. Ingram
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: SRPT
Employees835
IPO date1997-06-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.